FLT3 Mutations in AML: From Clinical Expression to Action
Knowing a patient’s mutation status could help direct their therapy, which could change the outlook for that patient and impact outcomes, according to Dr Naval Daver. Watch as he and his colleague from MD Anderson Cancer Center, Dr Naveen Pemmaraju, concisely review FLT3-ITD and FLT3-TKD mutations in patients with AML, and how these mutations may influence patient prognosis and treatment decisions.
Drs Daver and Pemmaraju have entered into written agreements with Astellas for payment for their services in connection with this program.
